

ClinArt attracts growth capital investment from KLSC and announces new management on board



Dear ClinArt,

It gives me great pleasure to announce the appointment of Dr Alaa Assem who assumed the position of ClinArt's Chief Executive Officer as of the 1st of August 2011.

Dr Assem is a well rounded professional who had worked in the pharmaceutical industry for over 20 years, in several leading multinational organizations across the Middle East including Sandoz, Lilly, Wyeth, and Pfizer with the last position held was Strategic Public Affairs Director - Middle East. Dr Assem brings to ClinArt an extensive and rich experience in managing clinical trials across the region and in accordance with the highest international standards, successfully supporting the registration and pricing of several new innovative products across the Africa and Middle East in different therapeutic areas. Dr Assem is a physician, holding an M.Sc in Ophthalmology from University of Alexandria (Egypt) and an MBA from Maastricht School of Management (Netherlands).

To capture on the continued growth of the CRO market and opportunities in the Africa and Middle East region, ClinArt is also pleased to announce that it has attracted an equity investment from Kuwait Life Sciences Company (KLSC) www.klsc.com.kw, an investment company which focuses on healthcare innovative concepts and demanded services that offer significant value to the healthcare sector in Kuwait, Gulf and Middle East. KLSC is fully owned by National Technology Enterprises Company www.ntec.com.kw. KLSC has funded ClinArt to continue its successful growth and expansion all over the Middle East. KLSC has been an active investor internationally and enjoys an extensive network in global healthcare industry.

I have no doubt in Dr Assem's expertise and leadership capabilities along with the commitment and vision of KLSC that will significantly contribute to further success of ClinArt and position it to capture the growth potential in the clinical research field in the AfME region by offering clients a comprehensive range of services for drug development accelerating delivery of products to market for patient benefit in the region.

On behalf of ClinArt team I welcome Dr. Alaa Assem on board and join hands together for building on the solid foundation and momentum achieved by ClinArt's team, I will continue to serve ClinArt as a member of the Board of Director's to enjoy ClinArt's continuing successes.

Kind Regards,
Maha Al-Farhan



ClinArt team welcomes you Dr. Assem.



Dr. Alaa Assem
CEO and Board
Member



Dr. Maha Al-Farhan
Founder and Board
Member



Kuwait Life Sciences
Company



National Technology
Enterprises
Company